靶向LETMD1的miR-494对宫颈癌发病的作用

李新; 董立新; 杨森; 曹丽艳; 毛羽; 付占昭; 董思奇

PDF(856 KB)

武警医学 ›› 2019, Vol. 30 ›› Issue (3) : 205-208.

论著

靶向LETMD1的miR-494对宫颈癌发病的作用

李新^1,2,董立新²,杨森²,曹丽艳²,毛羽²,付占昭²,董思奇³

作者信息 +

MiR-494 inhibits tumor progression by targeting LETMD1 in cervical cancer

LI Xin^1,2,DONG Lixin²,YANG Sen², CAO Liyan²,MAO Yu²,FU Zhanzhao²,DONG Siqi³

Author information +

文章历史 +

摘要

目的探讨靶向作用于LETMD1的miR-494对宫颈癌发病的作用。方法选取2017-09至2018-03诊断为原发性宫颈癌、接受根治性子宫切除及盆腔淋巴结清扫术30例的病理标本,另选取同期因妇科良性疾病行全子宫切除30例的正常宫颈组织病理标本。检测癌组织及正常组织中 miR-494和 LETMD1的表达。结果 miR-494在宫颈癌组织中含量明显降低,与LETMD1表达呈明显负相关,且miR-494与肿瘤患者FIGO分期明显相关(P<0.05)。双荧光素酶报告实验证实miR-494直接作用于LETMD1 mRNA的3′UTR。集落形成试验证实miR-494通过靶向作用LETMD1抑制宫颈癌细胞的增殖。结论宫颈癌患者miR-494与FIGO分期明显相关,miR-494可通过靶向作用于LETMD1 抑制宫颈癌细胞的增殖。

Abstract

Objective To explore the role of LETMD1-targeting miR-494 in the progression of cervical cancer.Methods miRNA-494 mRNA and LETMD1 protein expressions in clinical samples were determined to confirm the effects on cell proliferation, invasion and migration.Results The expression of miR-494 in tissue samples of cervical cancer was significantly decreased, and its expression level was negatively correlated with the FIGO stage (P<0.05). LETMD1 was identified as a target gene of miR-494 in cervical cancer cells by dual-luciferase assay. Functional experiments demonstrated that miR-494 could inhibit the cell proliferation via the negative regulation of LETMD1 expression.Conclusions Our findings provide important evidence for the role of miR-494 as a tumor suppressor in cervical cancer via the inhibition of LETMD1 expression.

导出引用

李新,董立新,杨森,曹丽艳,毛羽,付占昭,董思奇. 靶向LETMD1的miR-494对宫颈癌发病的作用[J]. 武警医学. 2019, 30(3): 205-208

LI Xin,DONG Lixin,YANG Sen, CAO Liyan,MAO Yu,FU Zhanzhao,DONG Siqi. MiR-494 inhibits tumor progression by targeting LETMD1 in cervical cancer[J]. Medical Journal of the Chinese People Armed Police Forces. 2019, 30(3): 205-208

中图分类号： R361.1

参考文献

[1] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015,136(5):E359-386.
[2] Torre L A, Bray F, Siegel R L, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015,65(2):87-108.
[3] Ko J, Lee Y H, Hwang S Y, et al. Identification and differential expression of novel human cervical cancer oncogene HCCR-2 in human cancers and its involvement in p53 stabilization[J]. Oncogene, 2003,22(30):4679-4689.
[4] Peralta Z O, Deas J, Meneses A A, et al. Relevance of miR-21 in regulation of tumor suppressor gene PTEN in human cervical cancer cells[J]. BMC Cancer, 2016,16:215.
[5] 董青川, 张治国, 程继, 等. miR-155对前列腺癌放射治疗的增敏作用[J]. 武警医学, 2017,28(1):60-63,67.
[6] Ha S A, Lee Y S, Shin S M, et al. Oncoprotein HCCR-1 expression in breast cancer is well correlated with known breast cancer prognostic factors including the HER2 overexpression, p53 mutation, and ER/PR status[J]. BMC Cancer, 2009,9:51.
[7] Xu Z, Zhang Y, Jiang J, et al. Epidermal growth factor induces HCCR expression via PI3K/Akt/mTOR signaling in PANC-1 pancreatic cancer cells[J]. BMC Cancer, 2010,10:161.
[8] Zhang J L, Liu X Z, Wang P Y, et al. Targeting HCCR expression resensitizes gastric cancer cells to chemotherapy via down-regulating the activation of STAT3[J]. Sci Rep, 2016,6:24196.
[9] Zhang G, Ha S A, Kim H K, et al. Combined analysis of AFP and HCCR-1 as an useful serological marker for small hepatocellular carcinoma: a prospective cohort study[J]. Dis Markers, 2012,32(4):265-271.
[10] 朱华强, 胡冬, 薛冰蓉. 抗-LETMD1在肝细胞癌临床诊断研究中的初步应用[J]. 检验医学与临床, 2010,13(7):1301-1303.
[11] Wezel A, Welten S M, Razawy W, et al. Inhibition of MicroRNA-494 reduces carotid artery atherosclerotic lesion development and increases plaque stability[J]. Ann Surg, 2015,262(5):841-848.
[12] Zhang Y, Guo L, Li Y, et al. MicroRNA-494 promotes cancer progression and targets adenomatous polyposis coli in colorectal cancer[J]. Mol Cancer, 2018,17(1):12.
[13] Zhang J, Wang T, Zhang Y, et al. Upregulation of serum miR-494 predicts poor prognosis in non-small cell lung cancer patients[J]. Cancer Biomark, 2018,21(4):763-768.
[14] Ma Y, Li G, Hu J, et al. MicroRNA-494 regulates Gli3 expression and inhibits pancreatic cancer cells growth and migration[J]. J Cell Biochem, 2018,119(7):5324-5331.
[15] Zhan M N, Yu X T, Tang J, et al. MicroRNA-494 inhibits breast cancer progression by directly targeting PAK1[J]. Cell Death Dis, 2017,8(1):2529.
[16] Chen B, Hou Z, Li C, et al. MiRNA-494 inhibits metastasis of cervical cancer through pttg1[J]. Tumour Biol, 2015,36(9):7143-7149.
[17] 陈建亮. miR-494通过抑制SIRT1表达调节人宫颈癌Hela细胞系增殖和迁移[J].实用预防医学, 2015,22(11):1390-1392.
[18] Cheng L, Kong B, Zhao Y, et al. miR-494 inhibits cervical cancer cell proliferation through upregulation of SOCS6 expression[J]. Oncol Lett, 2018,15(3):3075-3080.